RC-3095 (TFA)

CAT:
804-HY-P0107A-01
Size:
1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
RC-3095 (TFA) - image 1

RC-3095 (TFA)

  • UNSPSC Description:

    RC-3095 TFA is a selective bombesin/gastrin releasing peptide receptor (GRPR) antagonist[1]. RC-3095 TFA exerts protective effects by reducing gastric oxidative injury in the arthritic mice[2].
  • Target Antigen:

    Bombesin Receptor
  • Type:

    Peptides
  • Related Pathways:

    GPCR/G Protein
  • Applications:

    COVID-19-immunoregulation
  • Field of Research:

    Inflammation/Immunology
  • Assay Protocol:

    https://www.medchemexpress.com/rc-3095-tfa.html
  • Purity:

    98.12
  • Solubility:

    H2O : 40 mg/mL (ultrasonic)
  • Smiles:

    O=C([C@H]1CC(C(C=CC=C2)=C2N3)=C3CN1)N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@@H](C)C(N[C@@H](C(C)C)C(NCC(N[C@H](C(N[C@@H](CC(C)C)CN[C@H](C(N)=O)CC(C)C)=O)CC4=CN=CN4)=O)=O)=O)=O)CC5=CNC6=C5C=CC=C6)=O.OC(C(F)(F)F)=O
  • Molecular Weight:

    1220.34
  • References & Citations:

    [1]Oliveira PG, et al. Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. Arthritis Rheum. 2011 Oct;63(10):2956-65.|[2]Roesler R, et al. RC-3095, a bombesin/gastrin-releasing peptide receptor antagonist, impairs aversive but not recognition memory in rats. Eur J Pharmacol. 2004 Feb 13;486(1):35-41.
  • Shipping Conditions:

    Blue Ice
  • Storage Conditions:

    -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
  • Clinical Information:

    No Development Reported
  • CAS Number:

    1217463-61-0